S851
Clinical - Lung
ESTRO 2026
and compared using the Chi-square or Fisher’s exact test, as appropriate. Progression-free survival (PFS) was estimated by the Kaplan–Meier method for patients with ≥ 6 months of follow-up and compared between groups using the log-rank test. Median survival times and survival rates were reported with 95% confidence intervals (CIs). Results: Enrollment began on September 11, 2023, at a single tertiary cancer center in Italy. As of November 12, 2025, 194 patients met the inclusion criteria, including 34 in the SBRT group and 159 in the surgery group. The main baseline characteristics for the overall population and treatment subgroups are summarized in Table 1.
Conclusion: Preliminary results confirm the expected differences in baseline clinical conditions between the two treatment groups, without selection bias regarding stage or histology. Survival outcomes appear comparable between SBRT and surgery. While enrollment is ongoing, translational analyses have been started to explore associations between clinical parameters and multi-omic response profiles. References: Volpe, S., Zaffaroni, M., Piperno, G. et al. Multi-omics integrative modelling for stereotactic body radiotherapy in early-stage non-small cell lung cancer: clinical trial protocol of the MONDRIAN study. BMC Cancer23, 1236 (2023). https://doi.org/10.1186/s12885-023-11701-9 Keywords: ES-NSCLC, multi-omics signature, outcome modelling Role of Radiotherapy Approach, Molecular Profile, Time to CNS Involvement and Systemic Treatment as Predictors of NSCLC Brain Metastases Outcomes Nikolay Tolev 1 , Magdalena Kisimova 1 , Georgi Ganev 1 , Dimo Dimov 1 , Veselina Yanakieva 1 , Yavor Yurukov- Tozzini 1 , Manuela Vartanyan 2 , Stanislav Koychev 1 , Rositsa Krasteva 3 , Zahari Zahariev 1 1 Radiation Oncology, Uni Hospital, Panagyurishte, Bulgaria. 2 Radiation Oncology, “Dr. Marko A. Markov” Oncology Hospital,, Varna, Bulgaria. 3 Medical Oncology, Uni Hospital, Panagyurishte, Bulgaria Digital Poster 4774 Purpose/Objective: This single-institution retrospective study at Uni Hospital, Bulgaria, aimed to evaluate overall survival (OS) and intracranial disease control in non-small cell lung cancer (NSCLC) patients with brain metastases, with a focus on the impact of molecular status, radiotherapy modality and frequency, timing of CNS lesions and type of systemic therapy given. Material/Methods: Between August 2017 and May 2025, a total of 498 NSCLC patients with brain metastases were treated, 102 were analyzed accounting for a total of 191
At univariate analysis, significant differences were found for age, ECOG performance status, Charlson Comorbidity Index, and presence of respiratory comorbidities. The median follow-up for the entire cohort was 11.8 months (range, 0–30 months). No significant difference in PFS was observed between the SBRT and surgery groups (Figure 1).
Made with FlippingBook - Share PDF online